Teva Sues Cipla to Block Generic Versions of Qvar Asthma Inhaler

Teva Pharmaceutical Industries Ltd.said Cipla Ltd.’s proposed generic version of an inhaler used to treat asthma infringes six patents for Teva’s Qvar.

• Teva is seeking a court order blocking copies until the patents have expired and cash compensation if copies are made before then, according to complaint filed Friday in federal court in Newark, New Jersey
• Five of the patents expire in May 2031 and one in January 2032: FDA Orange Book
• Qvar had North American sales of $97 million in the first half of 2020, 22% less than during the same period in 2019, Teva said Aug. ...